US Stock MarketDetailed Quotes
NYXH Nyxoah SA
- 7.710
- -2.410-23.81%
Trading May 23 15:03 ET
221.14MMarket Cap-4750P/E (TTM)
10.120High7.320Low210.53KVolume9.740Open10.120Pre Close1.76MTurnover1.92%Turnover RatioLossP/E (Static)28.68MShares20.00052wk High2.34P/B84.63MFloat Cap4.00052wk Low--Dividend TTM10.98MShs Float37.000Historical High--Div YieldTTM27.67%Amplitude4.000Historical Low8.336Avg Price1Lot Size
About Nyxoah SA Company
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.
Company Profile
SymbolNYXH
Company NameNyxoah SA
Listing DateJul 2, 2021
Issue Price27.00
Founded2009
CEOMr. Olivier Taelman
MarketNASDAQ
Employees147
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
AddressRue Edouard Belin 12
CityMont-Saint-Guibert
ProvinceWalloon Region
CountryBelgium
Zip Code1435
Phone32-10-22-23-55
Websitehttp://www.nyxoah.com
Company Executives
- Name
- Position
- Salary
- Olivier Taelman
- Chief Executive Officer and Director
- 807.10K
- Loic Moreau
- Chief Financial Officer
- 468.69K
- Robert Taub
- Non-Executive Chairman of the Board
- 127.63K
- Dr. Pierre Gianello, M.D.
- Director
- 175.63K
- Dr. Jurgen Hambrecht, PhD
- Independent Director
- 58.50K
- Kevin Rakin
- Independent Director
- 68.59K
- Daniel George Wildman
- Independent Director
- 71.28K
- Virginia M. Kirby
- Independent Director
- 59.22K
- Rita Johnson-Mills
- Independent Director
- 63.62K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg